MicroRNA-200b is a potential biomarker of the expression of PD-L1 in patients with lung cancer

Seigo Katakura¹, Nobuaki Kobayashi¹, Hisashi Hashimoto¹, Chisato Kamimaki¹, Katsushi Tanaka¹, Sousuke Kubo¹, Kentaro Nakashima¹, Shuhei Teranishi², Saki Manabe², Keisuke Watanabe¹, Nobuyuki Horita¹, Yu Hara¹, Masaki Yamamoto², Makoto Kudo², Hongmei Piao³ & Takeshi Kaneko¹

¹ Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
² Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, Japan
³ Department of Respiratory Medicine, Affiliated Hospital of Yanbian University, Yanji, China

Keywords
Biomarkers; exosomes; miRNA; non-small cell lung cancer; programmed cell death
1 ligand 1.

Correspondence
Nobuaki Kobayashi, Yokohama City University Graduate School of Medicine, Fukuura 3-9 Kanazawa-Ku, Yokohama 236-0004, Japan.
Tel: +81-45-787-2800
Fax: +81-45-352-7963
Email: nkobayas@yokohama-cu.ac.jp

Received: 13 June 2020;
Accepted: 20 August 2020.
doi: 10.1111/1759-7714.13653

Thoracic Cancer 11 (2020) 2975–2982

Abstract

Background: Advanced non-small cell lung cancer (NSCLC) has a high mortality rate and poor prognosis. However, outcomes have gradually improved after the introduction of novel immunotherapies, including immune checkpoint inhibitors (ICIs). Although programmed death-ligand 1 (PD-L1) expression in tumor tissues is a known biomarker for guiding ICI treatment of NSCLC, challenges such as difficulty of liquid biopsy and heterogeneous results during treatment persist. This study evaluated the potential of miR200b as a surrogate biomarker for PD-L1 expression.

Methods: We used the human lung cancer cell lines H226, H460, H520, A549, and H1975. miR200b expression in blood and bronchoscopy specimens of NSCLC patients was evaluated using reverse-transcription-quantitative PCR. Using flow cytometry, PD-L1 expression in vitro, as well as in tumor tissues, was evaluated after transfection with a mimic miR200b or siRNA.

Results: miR200b expression negatively correlated with PD-L1 expression in all cell lines. The induction or knockdown of miR200b also altered PD-L1 expression in vitro. The patient group with a PD-L1 tumor proportion score ≥ 50% had significantly lower miR200b expression in the bronchoscopy specimens (P = 0.025) and serum-derived exosomes (P = 0.022) than that with PD-L1 tumor proportion score < 50%.

Conclusions: miR200b can regulate PD-L1 expression in lung cancer cells, and miR200b expression in clinical specimens negatively correlated with PD-L1 expression. Thus, miR200b may be a useful surrogate biomarker for PD-L1 expression in lung cancer patients.

Key points

Significant findings of the study
• High PD-L1 expression was linked to low miR200b expression, whereas low PD-L1 expression was linked to high miR200b expression in human lung cancer patients. Thus, miR200b overexpression or silencing can control PD-L1 expression in cancer cells.

What this study adds
• We demonstrated the potential of miR200b as a surrogate biomarker for PD-L1 expression in lung cancer patients.
Introduction

The poor prognosis of non-small cell lung cancer (NSCLC) is largely attributed to the unresectable, advanced status of most patients at the time of diagnosis. In these advanced cases, the administration of therapeutic agents is the mainstay of treatment. Recently, immunotherapy with an immune checkpoint inhibitor (ICI), together with molecular targeted therapy, has improved the prognosis of advanced NSCLC.1–9

Although ICIs are effective in cases with high tumor mutation burden and high programmed death-ligand 1 (PD-L1) expression, the establishment of biomarkers that can more accurately predict treatment outcome is necessary as ICIs potentially have serious adverse events and are costly.10 Among biomarkers for predicting treatment outcome, the most established is PD-L1 expression assessed using the tumor proportion score (TPS) in tumor tissues.6–8 Nevertheless, a high PD-L1 TPS (≥50%) has only been associated with a 44.8% response rate to pembrolizumab monotherapy, indicating that the PD-L1 TPS alone is an insufficient biomarker.6 Furthermore, using PD-L1 expression to guide ICI treatment is limited as PD-L1 expression can vary according to the biopsy site, even for the same tumor,11, 12 and changes before and after chemotherapy.13–15 Finally, an optimal liquid biopsy method has not yet been established.

MicroRNAs (miRNAs) are single-stranded, small non-coding RNAs composed of approximately 22 bases and are involved in the post-transcriptional regulation of gene expression in eukaryotes. Furthermore, miRNAs can be useful biomarkers for various diseases as they are stably present in bodily fluids, including the blood, urine, and saliva.16 Several studies have indicated that some miRNAs are related to PD-L1 expression in cancer patients.17–18 Particularly, miR34a, miR200b, miR197, miR513, and miR570, and miR138-5p19–24 may be potential surrogate biomarkers for PD-L1 expression, although we focused on miR200b because our preliminary data indicated that only miR200b is negatively correlated with PD-L1 expression in NSCLC cell lines and clinical specimens from lung cancer patients (data not shown). Low miR200 expression in tumor tissues has been associated with poor differentiation, a greater likelihood of lymph node metastasis, and resistance to docetaxel and gefitinib, highlighting the relationship between low tumor miR200 expression and poor prognosis among NSCLC patients.25–27 Several reports have described the associations between PD-L1 expression and various miRNAs. However, to the best of our knowledge, the association between miRNAs and PD-L1 expression using clinical specimens has not yet been investigated. Therefore, this study evaluated the potential of miR200b as a surrogate biomarker for PD-L1 expression in lung cancer patients.

Methods

Cell lines and cultures

Human lung cancer cell lines H226, H460, H560, and A549 were obtained from the American Type Culture Collection, whereas H1975 was obtained from the Japanese Cancer Research Resources Bank. All cell lines were cultured at 37°C and 5% CO2 in RPMI 1640 medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (Biowest, Maine-et-Loire, France) and 1% Pen/Strep (Gibco, Waltham, MA, USA). All chemical reagents and antibodies were obtained from CELL Signaling Technology (Danvers, MA) unless otherwise stated.

Western blotting

The cultured cells were lysed using a cell lysis buffer (1:10 dilution) supplemented with protease/phosphatase inhibitor cocktail (1:100). After homogenization, the total protein concentration was quantified using a Nanodrop 2000 system (Thermo Fisher Scientific, Waltham, MA, USA). After 20 μg of protein was heated at 95°C for five minutes, the samples were separated using electrophoresis and 10% sodium dodecyl sulfate-polyacrylamide gel (BIORAD, Hercules, CA, USA) and subsequently transferred onto polyvinylidene difluoride membranes (Invitrogen, Carlsbad, CA, USA). The membranes were blocked for one hour using 5% nonfat dry milk in Tris-buffered saline and Tween 20 (1:10) and then probed overnight at 4°C with primary antibodies targeting PD-L1 (1:1000) and β-actin (1:1000). The membranes were washed and incubated for one hour at room temperature with HRP-linked secondary antibodies (1:2000), and the band intensities were quantified using an Image Quant LAS 500 system (GE Healthcare, Chicago, IL, USA).

Flow cytometry

The cultured cells were harvested using 1.0 mM EDTA and washed twice in ice-cold phosphate-buffered saline supplemented with 10% fetal bovine serum. The cells were incubated for 30 minutes at 4°C with APC-conjugated antibodies targeting human PD-L1 or APC-conjugated isotype control antibodies (1:20; BioLegend, San Diego, CA, USA). Flow cytometry was performed using a FACS Celesta system (BD, Franklin Lakes, NJ, USA), and data analysis was performed using the FlowJo software (v10, BD, Franklin Lakes, NJ, USA).
Immunofluorescence staining

Each cell line was cultured for 48 hours, and the cells were fixed on chamber slides using 4% paraformaldehyde for 10 minutes and permeabilized using 100% ice-cold methanol for 10 minutes. After blocking the cells with 3% bovine serum albumin for 60 minutes, the slides were stained overnight at 4°C using primary antibodies targeting PD-L1 (1:200). Next, secondary antibodies targeting rabbit IgG (1:1000) were added for 60 minutes. Staining was performed using the Antifade Reagent with DAPI (Cell Signaling Technology, Danvers, MA), and the cells were observed under a Keyence BZ-X800 fluorescence microscope (Osaka, Japan).

Total RNA isolation and reverse-transcription

Total RNA from the cell lines and bronchial brush cytology specimens was extracted using an RNeasy mini kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instructions. Total RNA was also extracted from the conditioned medium and serum-derived exosomes using a miRNeasy serum/plasma advanced kit (QIAGEN). The purity and the concentration of the extracted total RNA were measured using the Nanodrop 2000 system (Thermo Fisher Scientific). cDNA was reverse-transcribed using 10 ng of total RNA, a TaqMan MicroRNA Reverse-Transcription Kit (Applied Biosystems, Foster City, CA, USA), and the primers from TaqMan microRNA assays (Applied Biosystems, Foster City, CA, USA).

Polymerase chain reaction (PCR)

A previous report has indicated that miR200b is negatively correlated with PD-L1 expression.22 Thus, we performed reverse-transcription–quantitative PCR (RT-qPCR) using the reverse-transcription samples, TaqMan Universal PCR Master Mix (Thermo Fisher Scientific), and the primers from TaqMan microRNA assays (Applied Biosystems; assay ID: 002251) on CFX96 Touch Real-Time PCR Detection System (BIORAD) according to the manufacturer’s protocol. miRNA expression levels were normalized to U6 small nuclear RNA (Applied Biosystems; assay ID: 001973), and the differences in expression were measured relative to the control using the 2^ΔΔCq method (ΔCq = Cqtarget − Cqreference).

Mimicking and silencing miR200b

The cell lines were seeded for 24 hours before transfection with mimic miR200b (GeneDesign, Osaka, Japan), S-TuD miR200b (GeneDesign) as negative control (Invitrogen), or Stealth™ RNAi siRNAs (Invitrogen). Transfection was performed using Lipofectamine 2000 (final concentration: 10 nM; Invitrogen) according to the manufacturer’s protocol and analyzed after 48 hours. The sequences used were as follows: mimic miR200b (upstream primer, 5’-CAUCUUACUGGGCAGCAUUUGA-3’) and S-TuD miR200b (upstream primer, 5’-GACGCGGCUGGGAUCAUUAUCAUCAGCACUUGAUGAAUAUCUGGU-3’).

Patients and samples

All clinical procedures in this study were approved by the Yokohama City University Ethics Committee (approval number: A181129001) and conformed with the Declaration of Helsinki. Japanese patients with suspected primary lung cancer were prospectively recruited at the Yokohama City University Hospital and Yokohama City University Medical Center between December 2018 and March 2020. Samples were obtained from patients who provided informed consent for the research use of their bronchoscopy specimens. We selected cases that have been histologically diagnosed as NSCLC and evaluated the miRNA expression of the bronchial brush cytology and serum samples obtained before chemotherapy (Fig 1). Before RNA extraction, the red blood cells were removed from the bronchial brush cytology samples using a RBC lysis buffer (Biolegend, San Diego, CA, USA), and the exosomes were extracted from serum samples using a mirCURY Exosome Serum/Plasma Kit (QIAGEN). The TPS for PD-L1 expression was evaluated by a pathologist based on the immunohistochemical staining for PD-L1 (22C3 pharmDx; Dako, Carpenteria, CA, USA).

Statistical analysis

Data were analyzed using the JMP Pro software (v12, SAS institute, SAS Campus Drive, Cary, NC, USA). Intergroup differences were evaluated using the Mann-Whitney U test, and intergroup correlations were evaluated using the Pearson’s correlation coefficient. Data are presented as the mean ± standard error of the mean, unless otherwise stated, and P-values of <0.05 were considered statistically significant.

Results

PD-L1 expression is different in human lung cancer cell lines

We found high PD-L1 expression in the H226 and H460 cells and low PD-L1 expression in the H520, A549, and H1975 cells using flow cytometry (Fig 1a,b) and observed
similar results using western blotting (Fig 1c). Fluorescent immunohistochemistry also revealed high PD-L1 expression in the H226 and H460 cells and low PD-L1 expression in the H520 and A549 cells (Fig 1d).

miR200b expression is inversely related to PD-L1 expression

We found low miR200b expression in the H226 and H460 cells and high miR200b expression in the H520, A549, and H1975 cells (Fig 2a). Similar results were obtained when the conditioned medium was used for RNA extraction (Fig 2b). These results indicate that miR200b expression is inversely related to PD-L1 expression in human lung cancer cells.

PD-L1 expression in vitro is regulated by miR200b

PD-L1 expression was significantly reduced by mimic miR200b in H460 cells (with normally high PD-L1 expression), but was increased after silencing using S-TuD miR200b in H520 and A549 (with normally low PD-L1 expression) cells (Fig 3a-c, P < 0.05). These results indicate that miRNA200b regulates PD-L1 expression in human lung cancer cells.

miR200b is inversely related to PD-L1 expression in specimens from lung cancer patients

Patient characteristics are shown in Table 1, and the immunohistochemical expression of PD-L1 was categorized...
as low (<50%) or high (≥50%). We observed that the specimens with high PD-L1 expression had significantly lower miR200b expression (Fig 4a). There was a weak negative correlation (correlation coefficient: −0.37) between the PD-L1 TPS and the miR200b expression in lung cancer tissues (Fig 4b). Furthermore, in serum-derived exosomes, significantly lower miR200b expression was observed in patients with high PD-L1 expression (Fig 5a), and the miR200b expression exhibited a weak negative correlation (correlation coefficient: −0.36) with PD-L1 expression (Fig 5b). Further, we investigated the concordance of miR200b expression in lung cancer tissues and serum-derived exosomes and found a weak positive correlation (correlation coefficient: 0.30) (Fig 5c).

**Relationship between miR200b and PD-L1 expression in patients without driver oncogene mutation is also inverse**

PD-L1 expression is regulated differently in epidermal growth factor receptor (EGFR) gene wild-type and mutant cases. Therefore, the relationship between miR200b and PD-L1 expression in patients without the driver oncogene mutation was analyzed. Similar to the results above, a significantly lower miR200b expression in both lung cancer tissues and serum-derived exosomes was observed in patients with high PD-L1 expression (Fig 6a,c), (correlation coefficient: −0.44). Similar results were obtained for each correlation in each sample type (Fig 6b,d,e) (correlation coefficient: −0.37).

**Discussion**

This study revealed that miR200b may regulate PD-L1 expression in cancer cells and that miR200b expression is inversely related to PD-L1 expression in lung cancer patients. These findings suggest that miR200b might be a useful surrogate marker for PD-L1 expression in lung cancer patients, which could then be used to predict the clinical efficacy of ICI treatment.

miRNAs have various functions that influence biological processes, such as cell development, differentiation, and proliferation, as well as the maintenance of homeostasis and apoptosis. Moreover, miRNAs are useful biomarkers for various diseases because they are stable and simple to detect in pathological specimens, blood, urine, and saliva. Various applications of miRNAs, such as use as

**Table 1 Patient characteristics**

|                                | n = 29 |
|--------------------------------|--------|
| Age in years, median (range)   | 73 (45–86) |
| Male sex, n (%)                | 19 (65.5%) |
| Histology, n (%)               |        |
| Adeno                          | 16 (55.1%) |
| Squamous                       | 8 (27.6%) |
| NSCLC                          | 5 (17.2%) |
| PD-L1 TPS, n (%)               |        |
| 0%                             | 10 (34.5%) |
| 1–49%                          | 8 (27.6%) |
| ≥50%, n (%)                    | 11 (37.9%) |
| Driver mutation, n (%)         |        |
| *EGFR*                         | 5 (17.2%) |
| *ALK*                          | 2 (7.0%)  |
| Stage, n (%)                   |        |
| I                              | 5 (17.2%) |
| II                             | 3 (10.3%) |
| III                            | 10 (34.5%) |
| IV                             | 11 (37.9%) |

Adeno, adenocarcinoma; NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1; Squamous, squamous cell carcinoma; TPS, tumor proportion score.
diagnostic and chemoresistance biomarkers and therapeutic targets, have been reported for NSCLC.\textsuperscript{31–33} Particularly, the miR200 family, including miR200a, miR200b, miR200c, miR141, and miR429, regulates the epithelial phenotype of cancer cells. In tumors, miR200b is mainly involved in epithelial–mesenchymal transition via the zinc-finger E-box binding homeobox 1 and helps control tumor metastasis and progression.\textsuperscript{34} Several studies have indicated that the expression of some miRNAs is related to PD-L1 expression in cancer patients.\textsuperscript{17, 18} For example, PD-L1 expression is inversely related to miR34a in acute myeloid leukemia, miR200b and miR197 in NSCLC, miR513 in biliary epithelial cells, miR570 in hepatocellular carcinoma, and miR138-5p in colon cancer.\textsuperscript{19–24} Thus, miRNAs can be potential surrogate biomarkers for PD-L1 expression. A previous report has also indicated that the 3′-UTR of PD-L1 contains two sites for possible binding to members of the miR200 family (miR200a, miR200b, and miR200c), and that PD-L1 expression is directly regulated by the miR200 family based on the results of luciferase reporter assay.\textsuperscript{22} This study revealed that miR200b expression is inversely related to PD-L1 expression and that miR200b influenced PD-L1 expression in human lung cancer cells, although the underlying molecular mechanisms remain unclear. Determination of miR200b expression in serum samples might address these limitations as these specimens are simple to

![Figure 4](image1.png) **Figure 4** Relationship between miR200b expression and the PD-L1 tumor proportion score (TPS) in cells from lung cancer patients. (a) miR200b expression in human cancer cells collected via bronchoscopy was detected using RT-qPCR. PD-L1 expression was assessed immunohistochemically, and the patients were divided into two groups with high (<50%) and low (≥50%) PD-L1 expression. The P-values were determined using the Mann-Whitney U test. (b) The correlation between miR200b expression and the PD-L1 TPS was evaluated using Pearson’s correlation coefficients.

![Figure 5](image2.png) **Figure 5** Relationship between miR200b expression in serum-derived exosomes and the PD-L1 TPS in cells from lung cancer patients. (a) miR200b expression in serum-derived exosomes was detected using RT-qPCR, whereas PD-L1 expression was assessed immunohistochemically (<50% vs. ≥50%). The P-values were determined using the Mann-Whitney U test. (b) The correlation between miR200b expression in serum-derived exosomes and the PD-L1 TPS was analyzed using Pearson’s correlation coefficients. (c) The correlation between miR200b expression in lung cancer tissues and that in serum-derived exosomes was analyzed using Pearson’s correlation coefficients.
obtain and could be collected throughout the course of treatment.

This study has several limitations that merit consideration. First, we only evaluated 29 clinical specimens from two hospitals. Second, we did not evaluate the relationship between the clinical efficacy of ICI treatment and the expression of miR200b before or after ICI treatment because only seven patients had been treated with ICIs. Therefore, additional studies using larger samples are needed to examine the relationship between serum-derived exosomal expression of miR200b and ICI efficacy, as well as whether exosomal miR200b expression varies before, during, or after ICI treatment.

Taken together, our results indicate an inverse relationship between miR200b and PD-L1 expression. Further studies are necessary to validate the applicability of miR200b as a biomarker to guide ICI treatment in lung cancer patients.

Acknowledgments

This work was partially supported by the Japan Society for the Promotion of Science KAKENHI (grant number: JP1426830111).

Disclosure

The authors declare no conflicts of interest.

References

1. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380–8.
2. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239–46.
3. Yang JCH, Wu YL, Schuler M et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-lung 3 and LUX-lung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015; 16: 141–51.
4. Mok TS, Wu YL, Ahn MJ et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376: 629–40.
MicroRNA-200b for PD-L1 expression

5 Wu YL, Cheng Y, Zhou X et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial. *Lancet Oncol* 2017; 18: 1454–66.

6 Reck M, Rodriguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N Engl J Med* 2016; 375: 1823–33.

7 Paz-Ares L, Luft A, Vicente D et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *N Engl J Med* 2018; 379: 2040–51.

8 Gandhi L, Rodriguez-Abreu D, Gadgeel S et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N Engl J Med* 2018; 378: 2078–92.

9 Socinski MA, Jotte RM, Cappuzzo F et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. *N Engl J Med* 2018; 378: 2288–301.

10 Khoo L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review. *Ann Oncol* 2017; 28: 2377–85.

11 Nakamura S, Hayashi K, Imaoka Y et al. Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer. *PLOS One* 2017; 12: e0186192.

12 Munari E, Zamboni G, Marconi M et al. PD-L1 expression heterogeneity in non-small cell lung cancer: Evaluation of small biopsies reliability. *Oncotarget* 2017; 8: 90123–31.

13 Ock CY, Kim S, Keam B et al. Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. *Oncotarget* 2017; 8: 97920–7.

14 Choe EA, Cha YJ, Kim JH et al. Dynamic changes in PD-L1 expression and CD8(+) T cell infiltration in non-small cell lung cancer following chemoradiation therapy. *Lung Cancer* 2019; 136: 30–6.

15 Lacour M, Hilbrunner S, Lee SY et al. Adjuvant chemotherapy increases programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer recurrence. *Clin Lung Cancer* 2019; 20: 391–6.

16 Bhaskaran M, Mohan M. MicroRNAs: History, biogenesis, and their evolving role in animal development and disease. *Vet Pathol* 2014; 51: 759–74.

17 Wang Q, Lin W, Tang X et al. The roles of microRNAs in regulating the expression of PD-1/PD-L1 immune checkpoint. *Int J Mol Sci* 2017; 18: 2540.

18 Smolle MA, Prinz F, Calin GA, Pichler M. Current concepts of non-coding RNA regulation of immune checkpoints in cancer. *Mol Aspects Med* 2019; 70: 117–26.

19 Wang X, Li J, Dong K et al. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. *Cell Signal* 2015; 27: 443–52.

20 Zhao L, Yu H, Yi S et al. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. *Oncotarget* 2016; 7: 45370–84.

21 Fujita Y, Yagishita S, Hagiwara K et al. The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. *Mol Ther* 2015; 23: 717–27.

22 Chen L, Gibbons DL, Goswami S et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. *Nat Commun* 2014; 5: 5241.

23 Gong AY, Zhou R, Hu G et al. MicroRNA-513 regulates B7-H1 translation and is involved in IFN-γ-induced B7-H1 expression in cholangiocytes. *J Immunol* 2009; 182: 1325–33.

24 Guo W, Tan W, Liu S et al. MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma. *Tumour Biol* 2015; 36: 9049–57.

25 Ceppi P, Mudduluru G, Kumarswamy R et al. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. *Mol Cancer Res* 2010; 8: 1207–16.

26 Feng B, Wang R, Song HZ, Chen LB. MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. *Cancer* 2012; 118: 3365–76.

27 Liu Z, Yao L, Tan B, Li L, Chen B. Detection of microRNA-200b may predict the inhibitory effect of gefitinib on nonsmall cell lung cancer and its potential mechanism. *Oncol Lett* 2016; 12: 5349–55.

28 Ambros V. MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing. *Cell* 2003; 113: 673–6.

29 Maemura K, Watanabe K, Ando T et al. Altered editing level of microRNAs is a potential biomarker in lung adenocarcinoma. *Cancer Sci* 2018; 109: 3326–35.

30 Shan X, Zhang H, Zhang L et al. Identification of four plasma microRNAs as potential biomarkers in the diagnosis of male lung squamous cell carcinoma patients in China. *Cancer Med* 2018; 7: 2370–81.

31 Yang X, Zhang Q, Zhang M et al. Serum microRNA signature is capable of early diagnosis for non-small cell lung cancer. *Int J Biol Sci* 2019; 15: 1712–22.

32 Xu S, Li J, Chen L et al. Plasma miR-32 levels in non-small cell lung cancer patients receiving platinum-based chemotherapy can predict the effectiveness and prognosis of chemotherapy. *Medicine* 2019; 98: e17335.

33 Petrek H, Yu AM. MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential. *Pharmacol Res Perspect* 2019; 7: e00528.

34 Gibbons DL, Lin W, Creighton CJ et al. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. *Genes Dev* 2009; 23: 2140–51.